Clinical trial · Interventional
Post-First Progression Use of Bevacizumab in Metastatic Colorectal Cancer (mCRC)
Efficacy and Safety of Second-line Combination Chemotherapy With Avastin in Patients With Metastatic Colorectal Cancer Who Have Received First-line Chemotherapy Plus Avastin
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Bevacizumab beyond progression has been proven to be safe in the community setting (BRiTE) and in the post-marketing study (BEAT), and confirmed its efficacy and safety in the first line with all regimens of chemotherapy. A total of 1,953 patients were treated in BRiTE. At median follow-up of 17.5 mo, there were 1,369 1st PD and 839 deaths. Among patients with 1st PD, 65.2% received any 2nd-line chemotherapy, 34.8% received cetuximab, and 53.8% received BBP. In a multivariate analysis, Bevacizumab beyond first progression and exposure to any 2nd-line chemotherapy were independently associated with increased overall survival (both p \< 0.0001). Bevacizumab beyond progression appears to be associated with longer overall in BRiTE. The investigators planned a prospective study to prove this phenomenon of bevacizumab beyond progression.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bevacizumab (Avastin) | Drug | Bevacizumab | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Bevacizumab
- description
- Bevacizumab continuation plus chemotherapy in patients who have failed previous bevacizumab plus other chemotherapy
- interventionNames
- Drug: Bevacizumab (Avastin)
Primary outcomes (1)
- measure
- Progression free survival
- timeFrame
- 6 weeks
Secondary outcomes (2)
- measure
- Overall survival
- timeFrame
- 6 weeks
- measure
- Toxicity profiles
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically documented colorectal adenocarcinoma * Progression during first-line bevacizumab containing chemotherapy within 3 months * No serious toxicity to bevacizumab of 1st line treatment * Unresectable metastases * Uni-dimensional measurable lesion(s) by RECIST * Age over 18 years old * ECOG 0-2 * Adequate organ functions by clinical laboratory exams Exclusion Criteria: * Other tumor type than adenocarcinoma * CNS metastases * GI bleeding * Hypersensitivity to any of chemotherapeutic agents * Prior use of cetuximab or other targeted agents other than bevacizumab * Major surgery within 6 weeks * Other serious illness
References
Publications (1)
- RESULTHong YS, Lee J, Kim KP, Lee JL, Park YS, Park JO, Park SH, Kim SY, Baek JY, Kim JH, Lee KW, Kim TY, Kim TW. Multicenter phase II study of second-line bevacizumab plus doublet combination chemotherapy in patients with metastatic colorectal cancer progressed after upfront bevacizumab plus doublet combination chemotherapy. Invest New Drugs. 2013 Feb;31(1):183-91. doi: 10.1007/s10637-012-9853-3. Epub 2012 Jul 11. PMID 22782485